Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

y's 510(k) application for the MammoSite ML radiation therapy system for the treatment of early-stage breast cancer. With its multi-lumen design, this new device gives radiation oncologists the ability to shape the radiation dose for typical cases and treat patients who are otherwise not appropriate candidates for traditional brachytherapy. Hologic's MammoSite therapy system, first cleared by the FDA in 2002 as a single-lumen device, is the most widely used form of accelerated partial breast irradiation (APBI) in the United States. The MammoSite system is designed to provide the physician with the ability to deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days and enhancing patient comfort. Additionally, targeted therapy of the breast limits radiation exposure to normal, healthy tissue. The Company began a limited launch of the new MammoSite ML last month, and we anticipate a full commercial launch during the current quarter (quarter ending December 26, 2009).

CE marking for our ThinPrep integrated imager:

The integrated imager represents the latest innovation in cervical cancer screening by combining proven ThinPrep imaging technology and slide review into a single, convenient stand-alone device. The ThinPrep integrated imager is designed to provide the small and medium volume laboratory access to effective and efficient cytology screening technology, while allowing them the flexibility to address their specific productivity and throughput needs. The majority of laboratories in Europe would fall into the small or medium category. The integrated imager is designed to enable the cytotechnologist to perform slide review effectively and efficiently. The integrated imager can also be used as a conventional microscope saving valuable lab space.

Financial Guidance:

The Company's guidance for fiscal 2010 re
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  MiMedx Group, Inc. (NASDAQ: MDXG ), an ... and bioimplants processed from human amniotic membrane, announced today its ... Highlights include: , Revenue exceeds upper end ... $25.6 million , Quarter-over-quarter revenue grew ... increases 181% over Q2 2013 and 40% sequentially over Q1 ...
(Date:7/28/2014)... , July 28, 2014   Stone & ... of off-label marketing and fraud claims between the ... Solutions, Inc. ("VSI").  The settlement covers fraud in ... for endovenous laser ablation of varicose veins for ... firm with a history of representing whistleblowers in ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th , ... which has developed the AMAS cancer test, is making its ... To date, the test, which is a serum-based in vitro ... emerging as a significant tool in the fight against cancer ... With an estimated 17 million cancer survivors in the ...
Breaking Medicine Technology:MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:7/28/2014)... British researchers report that an alternative to the traditional ... their experiments, the scientists found that clasping hands transferred ... the other than what is known as a fist ... as a cultural substitute for the firm gripping of ... issue of the American Journal of Infection Control ...
(Date:7/28/2014)... do not divide unless there is enough oxygen present ... other cell types circumvent this rule. Researchers at The ... overrides the cells, warning signals, enabling cancers to continue ... the process, the researchers found that lysosomes the ... decisions. They also uncovered new evidence that certain drugs ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... Lake City, Utah (PRWEB) July 28, 2014 ... protein powders and drinks, announced that it will be ... drink line of products this summer. The additional flavors ... with clean pure taste-free protein , Inspire Pomegranate Razz ... Vanilla - flavor of soft-serve vanilla cone , Bariatric ...
(Date:7/28/2014)... UT Southwestern Medical Center cancer researchers have found ... the activity of a mutated cancer gene common ... SML-8-73-1 (SML), interferes with the KRAS gene, or ... produces proteins called K-Ras that influence when cells ... cells dividing uncontrollably and turning cancerous. These ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Cell's recycling center implicated in division decisions 2Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
... 2011. Researchers from the University of Maryland School of Medicine ... of exercise and computerized memory training to see if those ... The type of memory that will be examined is known ... and use it in a new way. Many ...
... (DECEMBER 12, 2011) Autism Speaks North America,s ... National Institutes of Health (NIH) in announcing the addition ... a data federation site for the National Database for ... will help create the largest multidisciplinary source of autism ...
... and lethal of all human brain tumors that originate ... followed by both radiation therapy and chemotherapy with temozolomide. ... temozolomide. A team of researchers led by Sameer Agnihotri, ... that the protein APNG can contribute to GBM resistance ...
... - Researchers from Boston University School of Medicine (BUSM) ... receptor (A2bAR) as a possible new therapeutic target against ... cholesterol. The findings, which appear on-line in Circulation ... is a metabolite produced naturally by cells at low ...
... New research from the laboratory of Dr. Elizabeth Leadbetter at ... of vaccines. Dr. Leadbetter,s lab has discovered new properties of ... for enhancing protection against a number of different infections. This ... of the journal Nature Immunology (Vol. 13, pp. ...
... by blocking the export of key control molecules from ... treatment for chronic lymphocytic leukemia (CLL) and other incurable ... at the Ohio State University Comprehensive Cancer Center ... Research Institute (OSUCCC James)., The agent, called KPT-SINE, ...
Cached Medicine News:Health News:Exercise/memory research for Parkinson's 2Health News:Exercise/memory research for Parkinson's 3Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 2Health News:Autism Speaks Autism Genetic Resource Exchange joins NIH National Database for Autism Research 3Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Trudeau Institute announces latest discovery in vaccine development 2Health News:Trudeau Institute announces latest discovery in vaccine development 3Health News:Novel export-inhibitor shows promise for treating CLL 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: